PLoS Pathogens (Apr 2017)

RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection.

  • Jeffrey Downey,
  • Erwan Pernet,
  • François Coulombe,
  • Benoit Allard,
  • Isabelle Meunier,
  • Joanna Jaworska,
  • Salman Qureshi,
  • Donald C Vinh,
  • James G Martin,
  • Philippe Joubert,
  • Maziar Divangahi

DOI
https://doi.org/10.1371/journal.ppat.1006326
Journal volume & issue
Vol. 13, no. 4
p. e1006326

Abstract

Read online

The type I interferon pathway plays a critical role in both host defense and tolerance against viral infection and thus requires refined regulatory mechanisms. RIPK3-mediated necroptosis has been shown to be involved in anti-viral immunity. However, the exact role of RIPK3 in immunity to Influenza A Virus (IAV) is poorly understood. In line with others, we, herein, show that Ripk3-/- mice are highly susceptible to IAV infection, exhibiting elevated pulmonary viral load and heightened morbidity and mortality. Unexpectedly, this susceptibility was linked to an inability of RIKP3-deficient macrophages (Mφ) to produce type I IFN in the lungs of infected mice. In Mφ infected with IAV in vitro, we found that RIPK3 regulates type I IFN both transcriptionally, by interacting with MAVS and limiting RIPK1 interaction with MAVS, and post-transcriptionally, by activating protein kinase R (PKR)-a critical regulator of IFN-β mRNA stability. Collectively, our findings indicate a novel role for RIPK3 in regulating Mφ-mediated type I IFN anti-viral immunity, independent of its conventional role in necroptosis.